Literature DB >> 24449075

5-ALA complete resections go beyond MR contrast enhancement: shift corrected volumetric analysis of the extent of resection in surgery for glioblastoma.

Philippe Schucht1, Sonja Knittel, Johannes Slotboom, Kathleen Seidel, Michael Murek, Astrid Jilch, Andreas Raabe, Jürgen Beck.   

Abstract

BACKGROUND: The technique of 5-aminolevulinic acid (5-ALA) tumor fluorescence is increasingly used to improve visualization of tumor tissue and thereby to increase the rate of patients with gross total resections. In this study, we measured the resection volumes in patients who underwent 5-ALA-guided surgery for non-eloquent glioblastoma and compared them with the preoperative tumor volume.
METHODS: We selected 13 patients who had received a complete resection according to intraoperative 5-ALA induced fluorescence and CRET according to post-operative T1 contrast-enhanced MRI. The volumes of pre-operative contrast enhancing tissue, post-operative resection cavity and resected tissue were determined through shift-corrected volumetric analysis.
RESULTS: The mean resection cavity (29 cm(3)) was marginally smaller than the pre-operative contrast-enhancing tumor (39 cm(3), p = 0.32). However, the mean overall resection volume (84 cm(3)) was significantly larger than the pre-operative contrast-enhancing tumor (39 cm(3), p = 0.0087). This yields a mean volume of resected 5-ALA positive, but radiological non-enhancing tissue of 45 cm(3). The mean calculated rim of resected tissue surpassed pre-operative tumor diameter by 6 mm (range 0-10 mm).
CONCLUSIONS: Results of the current study imply that (i) the resection cavity underestimates the volume of resected tissue and (ii) 5-ALA complete resections go significantly beyond the volume of pre-operative contrast-enhancing tumor bulk on MRI, indicating that 5-ALA also stains MRI non-enhancing tumor tissue. Use of 5-ALA may thus enable extension of coalescent tumor resection beyond radiologically evident tumor. The impact of this more extended resection method on time to progression and overall survival has not been determined, and potentially puts adjacent and functionally intact tissue at risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24449075     DOI: 10.1007/s00701-013-1906-7

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  32 in total

Review 1.  Neurosurgical oncology: advances in operative technologies and adjuncts.

Authors:  Randy S D'Amico; Benjamin C Kennedy; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2014-06-27       Impact factor: 4.130

2.  The influence of intraoperative resection control modalities on survival following gross total resection of glioblastoma.

Authors:  Marian C Neidert; Isabel C Hostettler; Jan-Karl Burkhardt; Malte Mohme; Ulrike Held; Reto Kofmehl; Günter Eisele; Christoph M Woernle; Luca Regli; Oliver Bozinov
Journal:  Neurosurg Rev       Date:  2016-02-09       Impact factor: 3.042

3.  FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.

Authors:  Philipp Lohmann; Pantelis Stavrinou; Katharina Lipke; Elena K Bauer; Garry Ceccon; Jan-Michael Werner; Bernd Neumaier; Gereon R Fink; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-16       Impact factor: 9.236

4.  Colour contrasting between tissues predicts the resection in 5-aminolevulinic acid-guided surgery of malignant gliomas.

Authors:  Tomasz Szmuda; Paweł Słoniewski; Wiktor Olijewski; Janusz Springer; Przemysław M Waszak
Journal:  J Neurooncol       Date:  2015-02-22       Impact factor: 4.130

Review 5.  To what extent will 5-aminolevulinic acid change the face of malignant glioma surgery?

Authors:  Ricardo Díez Valle; Sonia Tejada Solis
Journal:  CNS Oncol       Date:  2015-06-29

Review 6.  The value of extent of resection of glioblastomas: clinical evidence and current approach.

Authors:  Joao Paulo Almeida; Kaisorn L Chaichana; Jordina Rincon-Torroella; Alfredo Quinones-Hinojosa
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

7.  5-ALA fluorescence and laser Doppler flowmetry for guidance in a stereotactic brain tumor biopsy.

Authors:  Neda Haj-Hosseini; Johan C O Richter; Peter Milos; Martin Hallbeck; Karin Wårdell
Journal:  Biomed Opt Express       Date:  2018-04-20       Impact factor: 3.732

Review 8.  What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?

Authors:  Costas G Hadjipanayis; Georg Widhalm; Walter Stummer
Journal:  Neurosurgery       Date:  2015-11       Impact factor: 4.654

9.  Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells.

Authors:  Johnathan E Lawrence; Christopher J Steele; Richard A Rovin; Robert J Belton; Robert J Winn
Journal:  J Neurooncol       Date:  2015-12-07       Impact factor: 4.130

Review 10.  Various shades of red-a systematic analysis of qualitative estimation of ALA-derived fluorescence in neurosurgery.

Authors:  Marcel A Kamp; Zarela Krause Molle; Christopher Munoz-Bendix; Marion Rapp; Michael Sabel; Hans-Jakob Steiger; Jan F Cornelius
Journal:  Neurosurg Rev       Date:  2016-05-25       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.